

Walter Reinisch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3395385/publications.pdf>

Version: 2024-02-01

133
papers

11,829
citations

76326

40
h-index

29157

104
g-index

137
all docs

137
docs citations

137
times ranked

8978
citing authors

#	ARTICLE	IF	CITATIONS
1	Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 1-8.	1.9	7
2	Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinib. <i>Tissue Barriers</i> , 2023, 11, .	3.2	1
3	The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 716-725.	1.9	5
4	Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 116-125.e5.	4.4	23
5	Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). <i>Gut</i> , 2022, 71, 1078-1087.	12.1	18
6	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 234-245.	1.9	11
7	Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1579-1587.e2.	4.4	22
8	Clinical Decision Support Tool for Infliximab in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1192-e1195.	4.4	1
9	PEG and Mucosal Biofilms in Irritable Bowel Syndrome and Ulcerative Colitis. <i>Gastroenterology</i> , 2022, 162, 992-993.	1.3	2
10	Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1588-1597.e3.	4.4	12
11	Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1095-1104.e9.	4.4	21
12	Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1034-1044.	1.9	10
13	Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 591-600.	1.3	23
14	Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry. <i>Gastroenterology</i> , 2022, 162, 316-319.e5.	1.3	46
15	Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 616-624.	1.3	2
16	Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study. <i>Journal of Rheumatology</i> , 2022, 49, 320-329.	2.0	24
17	A Review of the Totality of Evidence for the Development and Approval of ABP710 (AVSOLA), an Infliximab Biosimilar. <i>Advances in Therapy</i> , 2022, 39, 44-57.	2.9	2
18	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 118-127.	8.1	49

#	ARTICLE	IF	CITATIONS
19	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. <i>Advances in Therapy</i> , 2022, 39, 2342-2364.	2.9	10
20	INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1737-1745.	1.9	19
21	The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis. <i>Inflammatory Bowel Diseases</i> , 2022, , .	1.9	7
22	Categorising Endoscopic Severity of Crohn's Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1011-1019.	1.3	6
23	Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. <i>Gastroenterology</i> , 2022, 162, 1650-1664.e8.	1.3	88
24	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2619-2627.e1.	4.4	9
25	Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1151-1159.	3.7	4
26	Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn's disease? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1040-1041.	3.7	1
27	Precision Medicine in Inflammatory Bowel Diseases: Challenges and Considerations for the Path Forward. <i>Gastroenterology</i> , 2022, 162, 1815-1821.	1.3	3
28	Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 832-840.	2.8	11
29	Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1555-1564.	1.9	5
30	Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2022, 117, 1106-1117.	0.4	28
31	Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210908.	3.2	0
32	Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases. <i>Vaccines</i> , 2022, 10, 759.	4.4	1
33	Observational data from the adalimumab postmarketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis. <i>United European Gastroenterology Journal</i> , 2022, 10, 485-495.	3.8	3
34	MANTA and MANTA-RAY: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases. <i>Advances in Therapy</i> , 2022, 39, 3403-3422.	2.9	26
35	Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 3316.	2.4	6
36	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 914-929.	1.3	29

#	ARTICLE	IF	CITATIONS
37	Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. <i>Gut</i> , 2021, 70, gutjnl-2020-320690.	12.1	17
38	Passive Smoking Increases the Risk for Intestinal Surgeries in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 379-385.	1.9	5
39	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 106-122.	1.9	14
40	Impact of various central endoscopy reading models on treatment outcome in Crohn's disease using data from the randomized, controlled, exploratory cohort arm of the BERGAMOT trial. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 174-182.e2.	1.0	11
41	Effect of IBD medications on COVID-19 outcomes: results from an international registry. <i>Gut</i> , 2021, 70, 725-732.	12.1	240
42	Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2374-2384.	2.4	6
43	Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn's Disease: A Post Hoc Analysis of the IM-UNITI Trial. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 848-854.	1.9	11
44	Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 462-470.	1.3	16
45	Inflammatory Bowel Disease and Risk of Major Bleeding During Anticoagulation for Venous Thromboembolism. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1773-1783.	1.9	8
46	P117...Filgotinib reduces markers of JAK1 signaling in Crohn's disease: concordance with endoscopy and histopathology. , 2021, , .		0
47	Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110057.	3.2	20
48	Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 938-949.	1.3	23
49	Colectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1963-1967.	1.9	0
50	Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affairs Healthcare System. <i>Gut</i> , 2021, 70, 1657-1664.	12.1	42
51	Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1649-1657.	1.3	10
52	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. <i>Gastroenterology</i> , 2021, 160, 1570-1583.	1.3	1,054
53	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	0
54	The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies. <i>United European Gastroenterology Journal</i> , 2021, 9, 581-589.	3.8	21

#	ARTICLE	IF	CITATIONS
55	Immunologically relevant aspects of the new COVID-19 vaccines – an –GAI (Austrian Society for) Tj ETQq1 1 0.784314 rgBT /Over bo Allergo Journal International, 2021, 30, 155-168.	2.0	6
56	Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology, 2021, 160, 2340-2353.	1.3	93
57	New Gastrointestinal Symptoms Are Common in Inflammatory Bowel Disease Patients With COVID-19: Data From an International Registry. Inflammatory Bowel Diseases, 2021, , .	1.9	9
58	Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. BMJ, The, 2021, 374, n1554.	6.0	136
59	Role of fecal calprotectin in predicting endoscopic recurrence in postoperative Crohn's disease. Scandinavian Journal of Gastroenterology, 2021, 56, 1169-1174.	1.5	6
60	External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease. Pharmaceutics, 2021, 13, 1368.	4.5	13
61	Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology, 2021, 161, 715-718.e4.	1.3	102
62	Epithelial Neutrophilic Infiltrate: The Rising Star in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0
63	COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States. Clinical Gastroenterology and Hepatology, 2021, 19, 2210-2213.e3.	4.4	4
64	Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection. Journal of Clinical Pharmacology, 2021, 61, 224-233.	2.0	8
65	End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease. Journal of Crohn's and Colitis, 2021, 15, 1114-1119.	1.3	9
66	Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Alimentary Pharmacology and Therapeutics, 2021, 54, 1442-1453.	3.7	4
67	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open, 2021, 4, e2129639.	5.9	86
68	Letter to the Editor Regarding –Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland –. Advances in Therapy, 2021, 39, 811.	2.9	2
69	Inflammatory Bowel Disease Patients – Perspectives of Clinical Trials: A Global Quantitative and Qualitative Analysis. Crohn's & Colitis 360, 2021, 3, .	1.1	3
70	Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflammatory Bowel Diseases, 2020, 26, 304-313.	1.9	17
71	Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 1063-1075.	8.1	35
72	Reply. Gastroenterology, 2020, 158, 2307.	1.3	0

#	ARTICLE	IF	CITATIONS
73	Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1236-1245.	0.4	23
74	Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. <i>Gastroenterology</i> , 2020, 159, 481-491.e3.	1.3	613
75	Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1209-1210.	3.7	1
76	Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0233781.	2.5	32
77	Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. <i>Gut</i> , 2020, 69, 658-664.	12.1	21
78	Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S815-S819.	1.3	7
79	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 139-147.	1.3	126
80	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1562-1571.	1.9	27
81	Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 163-171.	1.9	6
82	Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1068-1076.	3.7	132
83	Competition for Clinical Trials in Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019, 157, 1457-1461.e2.	1.3	44
84	Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1148-1157.	1.3	10
85	Response to Letter by Moulton et al.. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e99-e99.	1.9	0
86	Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1227-1233.	1.3	7
87	Efficacy and Safety of Abilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2019, 156, 946-957.e18.	1.3	66
88	Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1522-1531.	1.9	16
89	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 139-147.	4.4	138
90	Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1255-1261.	1.9	36

#	ARTICLE	IF	CITATIONS
91	Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 411-418.e3.	4.4	40
92	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1673-1679.e1.	4.4	26
93	Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 803-810.	1.9	28
94	Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. <i>Gut</i> , 2018, 67, 1824-1835.	12.1	87
95	Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 790-802.	2.0	37
96	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1334-1342.e4.	1.3	331
97	Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating \hat{I}^{27+} T Cells in Crohn's Disease: Report of the TOSCA Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 188-196.	1.3	24
98	Burden and outcomes for complex perianal fistulas in Crohn's disease: Systematic review. <i>World Journal of Gastroenterology</i> , 2018, 24, 4821-4834.	3.3	59
99	PWE-049â€¦Assessment of symptomatic hypophosphatemia with iron isomaltoside in inflammatory bowel disease patients. , 2018, , .		0
100	Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE). <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3430-3441.	3.0	11
101	Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2018, 155, 1008-1011.e8.	1.3	56
102	Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S669-S677.	1.3	39
103	Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , 2018, 50, 1019-1029.	0.9	20
104	Open : Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-up in the PYRAMID Registry. <i>American Journal of Gastroenterology</i> , 2018, 113, 872-882.	0.4	58
105	Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1053-1066.	1.3	17
106	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017, 376, 1723-1736.	27.0	1,232
107	Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017, 390, 135-144.	13.7	157
108	Exposureâ€“efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 921-929.	1.3	130

#	ARTICLE	IF	CITATIONS
109	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2779-2789.	13.7	633
110	Tofacitinib for Maintenance Therapy in Patients With Active Ulcerative Colitis in the Phase 3 OCTAVE Sustain Trial: Results by Local and Central Endoscopic Assessments. <i>American Journal of Gastroenterology</i> , 2017, 112, S329-S330.	0.4	4
111	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. <i>Lancet, The</i> , 2016, 388, 1281-1290.	13.7	771
112	Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jjw178.	1.3	17
113	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 380-388.e4.	1.3	114
114	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	1.3	251
115	Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 418-428.	1.3	60
116	Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. <i>Digestive and Liver Disease</i> , 2015, 47, 356-364.	0.9	33
117	Factors Associated With Short- and Long-Term Outcomes of Therapy for Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 539-547.e2.	4.4	71
118	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. <i>Gastroenterology</i> , 2015, 148, 1035-1058.e3.	1.3	323
119	Biosimilar safety factors in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, S9-S15.	3.4	39
120	Introduction and commentary: Biosimilars' clinical trial and safety considerations. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, S1.	3.4	1
121	A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1226-1233.	1.5	28
122	Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. <i>Gut</i> , 2014, 63, 88-95.	12.1	411
123	Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2014, 147, 1296-1307.e5.	1.3	280
124	Extracorporeal Photopheresis (ECP) in Patients with Steroid-dependent Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 293-300.	1.9	41
125	A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED). <i>American Journal of Gastroenterology</i> , 2013, 108, 1877-1888.	0.4	123
126	State of the iron: How to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 429-440.	1.3	71

#	ARTICLE	IF	CITATIONS
127	Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity. <i>Gastroenterology</i> , 2013, 145, 987-995.	1.3	354
128	Validation of Endoscopic Activity Scores in Patients With Crohn's Disease Based on a Post Hoc Analysis of Data From SONIC. <i>Gastroenterology</i> , 2013, 145, 978-986.e5.	1.3	155
129	52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1700-1709.	1.9	75
130	P-141 Association Between Week 8 Mayo Subscores and Hospitalisation Rates in Adalimumab-treated Patients with Ulcerative Colitis from ULTRA1 and ULTRA2. <i>Inflammatory Bowel Diseases</i> , 2013, 19, S80.	1.9	1
131	Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). <i>Gut</i> , 2012, 61, 535-542.	12.1	463
132	Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial. <i>Gastroenterology</i> , 2012, 142, 1102-1111.e2.	1.3	485
133	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. <i>Gut</i> , 2011, 60, 780-787.	12.1	750